This infosheet provides information on the clinical studies annex that must be attached for calls that involve clinical studies.
Published on | 9 months ago
Last updated on | 7 months ago
For calls that involve clinical studies (mainly under Horizon Europe Health Cluster, Cancer Mission, the Global Health-EDCTP3 Joint Undertaking and the Innovative Health Initiative (IHI)) applicants must add the Clinical Studies Annex to their proposal application and upload it as separate annex in the Submission System. Find the most recent version of the Annex attached ('information-on-clinical-studies-he-en').
Clinical studies have a number of methodological, operational and regulatory specificities. Information on these issues is crucial for evaluators to assess the scientific quality and operational feasibility of the proposal. Information provided on this in the annex does not need to be repeated elsewhere in the proposal but can be referred to. There are no page limitations for this annex, but the Commission asks to keep explanations as consice as possible.
Single-stage and stage-2 proposals: The use of this template is mandatory for single-stage or stage-2 proposals, if the application includes a clinical study AND it concerns a topic including clinical studies. For these topics, you will have the possibility to upload the completed template as a separate part of your application in the submission system.
Stage-1 proposals: In the limited frame of a stage-1 proposal, not all methodological details of clinical studies can be fully elaborated. Depending on the characteristics of the study, however, key aspects of clinical study have to be convincingly addressed already at stage 1. This template cannot be uploaded as a separate document at stage 1, but relevant aspects of this information should be integrated in part B of the stage 1 proposal template.
Single-stage and stage-2 proposals: The use of this template is mandatory for all clinical studies. You can upload the completed template as a separate part of your application in the submission system.
Stage-1 proposals: see under Horizon Europe collaborative R&I proposals
The Commission instructs applicants to use the section headings of the clinical studies annex as an orientation and provide the related information in sections B.1 and B.3 of the proposal, if the submission system does not provide the possibility to upload the template.
Clinical study covers clinical studies/trials/investigations/cohorts and means, for the purpose of this document, any systematic prospective or retrospective collection and analysis of health data obtained from individual patients or healthy persons in order to address scientific questions related to the understanding, prevention, diagnosis, monitoring or treatment of a disease, mental illness, or physical condition. It includes but it is not limited to clinical studies as defined by Regulation 536/2014 (on medicinal products), clinical investigation and clinical evaluation as defined by Regulation 2017/745 (on medical devices), performance study and performance evaluation as defined by Regulation 2017/746 (on in vitro diagnostic medical devices).
In April 2023, the clinical studies annex was updated in order to include a reference to the mandatory use of Clinical Trials Information System (CTIS). What you need to know about CTIS:
If your application includes clinical trials, note that the EU pharmaceutical legislation known as the Clinical Trials Regulation No 536/2014 entered into application on 31 January 2022, repealing the Clinical Trials Directive (EC) No. 2001/20/EC and national implementing legislation in the EU Member States, which regulated clinical trials in the EU until the Regulation's entry into application. As a result, from 31 January 2023, all initial clinical trial applications in the EU must be submitted via the Clinical Trials Information System (CTIS). CTIS is now the single-entry point for sponsors and regulators of clinical trials for the submission and assessment of clinical trial data.
The Clinical Trials Regulation foresees a three-year transition period, from 2022 to 2025. By 31 January 2025, all ongoing trials that were approved under the Clinical Trials Directive will be governed by the new Regulation and will have to be transitioned to CTIS.
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The RUSTICA project obtained funding under Horizon 2020, more in particular under the topic ‘Closing nutrient cycles’. RUSTICA focuses on demonstration and implementation of circular bio-based nutrient valorisation chains, focusing on waste from the fruit and vegetable agro-food system. The project kicked off in 2021 and will run until 2024. It will use a strong multi-actor approach to co-create both socio-economic and technological knowledge in four case study regions in Europe and one in Colombia. The Flanders-based company DRANCO is one of the project partners and acts as technical project manager for the entire project. DRANCO participates in the project to develop its own technologies, to network and to help make the transition to a more circular based economy.